IRIS
CORSARO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.783
Totale 7.783
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.783
Totale 7.783
Salva come PNG Salva come JPEG
Città #
Genova 5.648
Rapallo 842
Genoa 693
Vado Ligure 574
Bordighera 26
Totale 7.783
Salva come PNG Salva come JPEG
Nome #
Amyloid precursor protein modulates ERK1/2 signaling 161
Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm 157
Pharmacological activation of autophagy favors the clearing of intracellular aggregates of misfolded prion protein peptide to prevent neuronal death 156
Calcium binding promotes Prion Protein fragment 90-231 conformational change toward a membrane destabilizing and cytotoxic structure 156
Dual modulation of ERK1/2 and p38 MAP kinase activities induced by minocycline reverses the neurotoxic effects of the prion protein fragment 90-231 153
Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells 153
Characterization of the pro-apoptotic intracellular mechanisms induced by a toxic conformer of the recombinant human prion protein fragment 90-231 150
Apoptotic cell death and impairment of L-type voltage sensitive calcium channel activity in rat cerebellar granule cells treated with the prion protein fragment 106-126 150
Amyloid precursor protein and Presenilin 1 interaction studied by FRET in human H4 cells. 149
Basic fibroblast growth factor activates endothelial nitric-oxide synthase in CHO-K1 cells via the activation of ceramide synthesis 148
A critical concentration of N-terminal pyroglutamylated amyloid beta drives the misfolding of Ab1-42 into more toxic aggregates 147
In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity 139
Differential toxicity, conformation and morphology of typical initial aggregation states of Aβ1-42 and Aβpy3-42 beta-amyloids 138
Amyloid precursor protein and presenilin involvement in cell signaling 137
SDF1 controls pituitary cell proliferation through the activation of ERK1/2 and the Ca2+-dependent cytosolic tyrosine kinase, Pyk2. 136
Contribution of two conserved glycine residues to fibrillogenesis of the 106-126 prion protein fragment. Evidence that a soluble variant of the 106-126 peptide is neurotoxic 129
Different structural stability and toxicity of PrPARR and PrPARQ sheep prion protein variants 127
Amino-terminally truncated prion protein PrP90-231 induces microglial activation in vitro 126
Different Molecular Mechanisms Mediate Direct or Glia-Dependent Prion Protein Fragment 90–231 Neurotoxic Effects in Cerebellar Granule Neurons 125
Human PrP90-231-induced cell death is associated with intracellular accumulation of insoluble and protease-resistant macroaggregates and lysosomal dysfunction 124
p38 MAP Kinase mediates the cell death induced by PrP106-126 in the SH-SY5Y neuroblastoma cells 124
Celecoxib Inhibits Prion Protein 90-231-Mediated Pro-inflammatory Responses in Microglial Cells 124
Prion protein fragment 106-126 induces a p38 MAP kinase-dependent apoptosis in SH-SY5Y neuroblastoma cells independently from the amyloid fibril formation 124
Excitotoxicity Through NMDA Receptors Mediates Cerebellar Granule Neuron Apoptosis Induced by Prion Protein 90-231 Fragment 123
The phosphotyrosine phosphatase PTPh mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2 122
Different Effects of Human Umbilical Cord Mesenchymal Stem Cells on Glioblastoma Stem Cells by Direct Cell Interaction or Via Released Soluble Factors 121
Effects of Prion Protein on Aβ42 and Pyroglutamate-Modified AβpΕ3-42 Oligomerization and Toxicity 121
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 120
Role of prion protein aggregation in neurotoxicity 118
Conformation dependent pro-apoptotic activity of the recombinant human prion protein fragment 90-231 118
Expression in E. coli and purification of recombinant fragments of wild type and mutant human prion protein 117
High hydrophobic amino acid exposure is responsible of the neurotoxic effects induced by E200K or D202N disease-related mutations of the human prion protein 117
Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity 116
ERK1/2 and p38 MAP kinases control prion protein fragment 90-231-induced astrocyte proliferation and microglia activation 112
Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2 109
Chemokine stromal cell-derived factor 1α induces proliferation and growth hormone release in GH4C1 rat pituitary adenoma cell line through multiple intracellular signals 108
The chemokine SDF1/CXCL12: a novel autocrine/paracrine factor involved in pituitary adenoma development 108
Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity 107
Canine osteosarcoma cell lines contain stem-like cancer cells: Biological and pharmacological characterization 101
The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation 99
INTRACELLULAR MECHANISMS MEDIATING THE NEURONAL CELL DEATH AND ASTROGLIOSIS INDUCED BY THE PRION PROTEIN FRAGMENT 106-126 98
Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor 3 (SSTR3) mediated regulation of endothelial NOS and MAP kinase activities” 98
Recombinant human prion protein fragment 90-231, a useful model to study prion neurotoxicity 98
Nitric oxide production stimulated by the basic fibroblast growth factor requires the synthesis of ceramide 96
Neurodegeneration in Alzheimer disease: role of amyloid precursor protein and presenilin 1 intracellular signaling 95
Aminoterminally truncated human Prion protein fragment 90-231 forms intracellular aggregates and causes lysosomal loss of impermeability 94
Molecular mechanisms involved in the aggregation and fibril formation of the recombinant human prion fragment PrP90-231 93
Intracellular accumulation of a mild-denatured monomer of the human PrP fragment 90-231 (hPrP90-231), as possible mechanism of its neurotoxic effects 91
Identification of a conserved N-capping box important for the structural autonomy of the prion alpha 3-helix: the disease associated D202N mutation destabilizes the helical conformation 91
Emerging Role of Cellular Prion Protein in the Maintenance and Expansion of Glioma Stem Cells 91
Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma 91
Addressing thermal and mechanical stability of human prion protein with single molecule and ensemble measurements 85
Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells 83
In vitro effect of human recombinant leptin and expression of leptin receptors on growth hormone-secreting human pituitary adenomas 82
ACTIVATION OF AUTOPHAGY PATHWAY AS NEUROPROTECTIVE MECHANISM AGAINST AMYLOIDOGENIC PRION PEPTIDE 79
Prion protein fragment 90-231 induces microglia activation: role of ERK1/2 and p38 MAP kinases in nitric oxide production and CCL5 secretion 78
In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors 78
Prolonged treatment with alpha-glycerylphosphorylethanolamine facilitates the acquisition of an active avoidance behavior and selectively increases neuronal signal transduction in rats 78
Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt 76
Celecoxib, a COX-2 inhibitor, blocks microglial activation induced by a neurotoxic conformer of hPrP90-231 75
Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro 74
The activation of the phosphotyrosine phosphatase h (r-PTPh) is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation 73
Somatostatinergic control of Kaposi’s sarcoma growth through the inhibition of angiogenesis 73
Somatostatin controls Kaposi sarcoma growth through inhibition of angiogenesis 73
Expression of somatostatin receptors mRNA in human meningiomas and their implication in in vitro antiproliferative activity 68
Neurotoxicity of the recombinant prion protein fragment 90-231 in SH-SY5Y cells is dependent on its conversion in beta-structured-isoform 66
Study of the Molecular Mechanism Responsible of the Conformational Changes Induced by E200K and D202N Pathological PrP Mutation 66
Molecular mechanisms mediating the neuroprotective effects of quinacrine and minocycline on cell death induced by the prion protein fragment 90-231 (hPrP90-231) 66
Study of the molecular mechanisms responsible of the transition of the prion protein fragment 90-231 in a neurotoxic conformation. 60
Somatostatin receptor subtype-dependent regulation of NO release: involvement of different intracellular pathways 56
The interaction of humic substances with the human prion protein fragment 90-231 affects its protease K resistance and cell internalization 56
In vitro effect of human recombinant leptin and expression of leptin receptors on growth hormone-secreting human pituitary adenomas. Clin Endocrinol (Oxf). 2002 Oct;57(4):449-55. 51
New therapeutic strategies for Alzheimer’s disease by determination of structure and toxicity of oligomeric beta-amyloids aggregation states 44
The activation of the phosphotyrosine phosphatase eta is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation 43
N6-isopentenyladenosine hinders the vasculogenic mimicry in human glioblastoma cells through Src-120 catenin pathway modulation and RhoA activity inhibition 42
Antitumor Potential of Antiepileptic Drugs in Human Glioblastoma: Pharmacological Targets and Clinical Benefits 38
Human glioblastoma-derived cell membrane nanovesicles: a novel, cell-specific strategy for boron neutron capture therapy of brain tumors 35
Proteostasis unbalance in prion diseases: mechanisms of neurodegeneration and therapeutic targets 24
Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro 19
Prolonged treatment with α-glycerylphosphorylethanolamine facilitates the acquisition of an active avoidance behavior and selectively increases neuronal signal transduction in rats 6
Intracellular accumulation of a mild-denatured monomer of the human PrP fragment 90-231, as possible mechanism of its neurotoxic effects 3
Totale 7.956
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.631
article - articoli 22.518
book - libri 0
conference - conferenze 908
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 205
Totale 47.262
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.637 0 0 0 0 183 227 293 134 174 317 247 62
2020/2021555 41 58 52 40 61 39 39 58 34 57 36 40
2021/2022985 28 103 57 100 36 71 76 231 32 78 44 129
2022/2023985 71 56 11 91 166 171 3 97 148 5 154 12
2023/2024559 27 56 10 86 41 149 39 30 24 13 33 51
2024/2025600 56 117 60 200 167 0 0 0 0 0 0 0
Totale 7.956